Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.
Name:
PIIS1040842816301056.pdf
Size:
460.2Kb
Format:
PDF
Description:
Open access full text article
Affiliation
Institute of Hematology and Medical Oncology, 'L. & A. Seragnoli', University of Bologna, Bologna, ItalyIssue Date
2016-08
Metadata
Show full item recordAbstract
Brentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in ∼60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N=480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL.Citation
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. 2016, 104:65-70 Crit Rev Oncol HematolJournal
Critical Reviews in Oncology/HematologyDOI
10.1016/j.critrevonc.2016.04.019PubMed ID
27279289Type
ArticleLanguage
enISSN
1879-0461ae974a485f413a2113503eed53cd6c53
10.1016/j.critrevonc.2016.04.019
Scopus Count
Collections
Related articles
- Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
- Authors: Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N
- Issue date: 2018 Jul 12
- Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
- Authors: Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V
- Issue date: 2015 Sep
- Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
- Authors: Dada R, Zekri J, Al Saadi R
- Issue date: 2016 Jun
- The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
- Authors: Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F
- Issue date: 2016 Jan
- Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
- Authors: Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P, Bruno B
- Issue date: 2016